Novo Nordisk: Pipeline Progress Collides With Pricing Reality
Novo Nordisk’s shares have been hammered, losing roughly 46% over the past twelve months and trading at a…
Novo Nordisk’s Pipeline Progress and Pill Milestone Fail to Budge Stock From 46% Below High
Despite a 46.86% drop from its 52-week high, Novo Nordisk reports strong Wegovy pill uptake, promising clinical data,…
Novo Nordisk’s Pipeline Progress Collides With a Darkening Revenue Outlook
Novo Nordisk balances rare-disease wins and obesity pipeline data against a grim 2026 revenue forecast and rising competition…
Novo Nordisk Faces a Fork in the Road as Pipeline Progress Meets Profit Pressure
Novo Nordisk stock trades 50% below peak amid GLP-1 competition from Eli Lilly’s oral pill, regulatory wins, and…
U.S. Offshore Wind Projects Report Progress After Resuming Offshore Work
Three of the five offshore wind projects under construction in the northeast U.S. have each signaled this…